^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HAVCR2 expression

i
Other names: HAVCR2, Hepatitis A Virus Cellular Receptor 2, T-Cell Immunoglobulin And Mucin Domain-Containing Protein 3, T-Cell Immunoglobulin Mucin Family Member 3, T-Cell Immunoglobulin Mucin Receptor 3, T-Cell Membrane Protein 3, HAVcr-2, TIMD-3, TIMD3, TIM3, T Cell Immunoglobulin Mucin 3,Kidney Injury Molecule-3, CD366 Antigen, CD366, KIM-3, SPTCL, Tim-3, TIM-3
Entrez ID:
Related biomarkers:
5d
The emerging role of TIM -3 in colorectal: a promising target for immunotherapy. (PubMed, Expert Opin Ther Targets)
Understanding Tim-3's complicated network of interactions in CRC has significant consequences for the development of novel immunotherapeutic strategies targeted for restoring anti-tumor immune responses and improving patient survival. Tim-3 is an important and valuable target for CRC patient risk classification and treatment because it regulates a complex network of strategies for suppressing immune responses, including causing T cell exhaustion, increasing Treg (regulatory T-cell) proliferation, and altering antigen-presenting cell activity.
Review • Journal • IO biomarker
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
HAVCR2 expression
8d
Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis. (PubMed, Cancer Med)
The IME of HCC is closely related to AVT and AIF. e-AVT can enhance anti-tumor activities in the IME by alleviating inflammation and fibrosis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3)
|
LAG3 expression • HAVCR2 expression • CTLA4 expression
15d
CD33-CD123 IF-THEN gating reduces toxicity while enhancing the specificity and memory phenotype of AML-targeting CAR-T cells. (PubMed, Blood Cancer Discov)
These gated CAR-T cells exhibited lower expression of exhaustion markers (PD1, Tim3, LAG3, and CD39), higher frequency of memory T cells (CD62L+CD45RA+), and enhanced expansion. While targeting AML, the moderated circuit CAR signal also helped to mitigate cytokine release syndrome, potentially addressing one of the ongoing challenges in CAR-T immunotherapy.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CD123 (Interleukin 3 Receptor Subunit Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD33 (CD33 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
PD-1 expression • LAG3 expression • HAVCR2 expression
17d
Moxibustion inhibits the macrophage M1 polarization toll-like receptor 4/myeloid differentiation factor 88/nuclear factor kappa B signaling pathway by regulating T-cell immunoglobulin and mucin-containing protein-3 in rheumatoid arthritis. (PubMed, J Tradit Chin Med)
Moxibustion regulates the key target TIM-3 by acting on the Zusanli (ST36) and Shenshu (BL23) points, thereby inhibiting the M1 polarization of macrophages; that is, it inhibits the TLR4-MyD88-NF-κB signaling pathway, and finally achieves alleviation of pathological changes and anti-inflammatory effects.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TLR4 (Toll Like Receptor 4)
|
HAVCR2 expression
24d
Unveiling Tim-3 immune checkpoint expression in hepatocellular carcinoma through abdominal contrast-enhanced CT habitat radiomics. (PubMed, Front Oncol)
This study confirmed the importance of Tim-3 as a prognostic marker in HCC. The habitat radiomics model we developed effectively predicted intratumoral Tim-3 infiltration, providing valuable insights for the evaluation of ICI therapy in HCC patients.
Journal • IO biomarker
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
HAVCR2 expression • HAVCR2 overexpression
1m
Ubiquitination and degradation of MHC-II by Tim-3 inhibits antiviral immunity. (PubMed, Cell Immunol)
We have thus identified a novel mechanism by which Tim-3 mediates virus immune escape. Manipulating the Tim-3-MHC-II signaling pathway may provide a novel treatment for viral infections.
Journal • IO biomarker
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
HAVCR2 expression • MHC-II expression
1m
Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. (PubMed, Sci Immunol)
In hepatocellular carcinoma, DHHC9 expression correlated with TIM-3 expression in CD8+ T cells and NK cells, and high DHHC9 expression was associated with shorter survival in patients with high TIM-3. These findings demonstrate that palmitoylation of TIM-3 catalyzed by DHHC9 promotes its stability, resulting in immune exhaustion and impaired antitumor immunity.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
CD8 expression • HAVCR2 expression
1m
Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation. (PubMed, Cells)
These pro-inhibitory changes are also correlated with reduced levels of the activation marker CD69 and the pro-inflammatory cytokine IFNγ in CD4+ and CD8+ T cells, as well as NK cells from glioblastoma patients. Collectively, these data reveal that glioblastoma-mediated CD4+ and CD8+ T cell and NK cell suppression is due, at least in part, to dysregulated TIM-3 and BAT3 expression and the associated downstream immunoregulatory and dysfunctional effects.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
HAVCR2 expression
1m
Novel Peptide-Based 68Ga-Labeled Radiotracer for Preclinical Studies of TIM3 Expression. (PubMed, Mol Pharm)
Upon comparison of ex vivo and in vivo studies, one of them, the 68Ga-DOTA-P26 probe, demonstrated significant target specificity for TIM3. These results suggest that studying peptide probes targeting TIM3 will promote the process of TIM3-targeted drug research and is expected to guide the application of TIM3 immune checkpoint drugs in immunotherapy.
Preclinical • Journal • IO biomarker
|
IFNG (Interferon, gamma) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
HAVCR2 expression • HAVCR2 overexpression
2ms
Spatial context of immune checkpoints as predictors of overall survival in patients with resectable colorectal cancer independent of standard TNM stages. (PubMed, Cancer Res Commun)
We found that the spatial context of PD-1 and TIM-3 successfully predicted the overall survival of CRC patients independent of TNM stage. Dual targeting of PD-1 and TIM-3 in mouse tumor models inhibited tumor progression and reduced T-cell exhaustion, indicating a potential strategy for improving the clinical treatment of CRC.
Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
MSI (Microsatellite instability) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
MSI-H/dMMR • PD-1 expression • HAVCR2 expression
2ms
Unravelling the Reasons Behind Limited Response to Anti-PD Therapy in ATC: A Comprehensive Evaluation of Tumor-Infiltrating Immune Cells and Checkpoints. (PubMed, Endocr Pathol)
TIM3, the most frequently expressed ICP on CTL, followed by CTLA4, provides alternate therapeutic targets in ATC. The co-expression of multiple immune checkpoints is of great interest for ATC since these data also open the avenue for combination therapies.
Journal • PD(L)-1 Biomarker • IO biomarker • Immune cell
|
PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • LGALS9 (Galectin 9)
|
PD-L1 expression • PD-1 expression • HAVCR2 expression
2ms
Prognostic value of T regulatory cells and immune checkpoints expression in tumor-draining lymph nodes for oral squamous cell carcinoma. (PubMed, Front Immunol)
These insights upgrade the prognostic framework for OSCC and pave the way for individualized therapeutic strategies. The prognostic significance of TDLNs and a high expression of immune checkpoint inhibitors is a compelling argument for the adoption of neoadjuvant immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • FOXP3 (Forkhead Box P3) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
|
LAG3 expression • HAVCR2 expression • CTLA4 expression
2ms
T-Cell Immunoglobulin and Mucin Domain 3 (TIM-3) Gene Expression as a Negative Biomarker of B-Cell Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci)
TIM-3 gene expression allowed for significant differentiation between patients with malignant B-ALL and non-malignant healthy controls, with an area under the curve (AUC) of 0.706. The current study addressed the potential of reduced levels of TIM-3 as a negative biomarker for B-ALL patients.
Journal • IO biomarker
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
HAVCR2 expression
2ms
A novel strategy of co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in osteosarcoma. (PubMed, Front Immunol)
Mechanistically, C5/IL7-CAR-T cells displayed enhanced STAT5 signaling. These findings highlight the potential of CXCR5 and IL-7 co-expression to improve CAR-T cell therapy efficacy against osteosarcoma.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • IL7 (Interleukin 7) • MICA (MHC Class I Polypeptide-Related Sequence A) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
|
PD-1 expression • BCL2 expression • HAVCR2 expression • CXCL13 expression • CXCR5 expression
2ms
The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells. (PubMed, Pharmacol Res)
Understanding the function of anti-Tim-3 therapy in non-T cells can help elucidate the diverse responses observed in clinical patients, leading to better development of relevant therapeutic strategies. This review aims to discuss the role of Tim-3 in the TME and emphasize the impact of Tim-3 blockade in the tumor immune microenvironment beyond T cells.
Review • Journal
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
HAVCR2 expression
3ms
Acasunlimab in combination with pembrolizumab reinvigorates anti-tumor immunity in patients with previously treated metastatic non-small cell lung cancer (NSCLC) (SITC 2024)
The study was conducted in accordance with the International Council for Harmonisation E6(R2) guidelines on good clinical practice and the principles of the Declaration of Helsinki. All patients provided written informed consent.
Clinical • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
CD8 expression • HAVCR2 expression
|
PD-L1 IHC 22C3 pharmDx • GuardantOMNI
|
Keytruda (pembrolizumab) • acasunlimab (GEN1046)
3ms
TAM-tastic: from resistance to resilience in cancer. (PubMed, Trends Pharmacol Sci)
In a recent article, Vanmeerbeek et al. found that blocking TIM3 or VISTA on IL-4-supported TAMs, in combination with paclitaxel (PTX), reprogrammed TAMs to attack cancer cells, highlighting a potential new therapeutic strategy.
Journal
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL4 (Interleukin 4)
|
HAVCR2 expression
|
paclitaxel
3ms
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. (PubMed, Nat Cancer)
PD1 blockade as well as vaccination augmented the antitumor activity of CAR-NKT cells. In summary, our results demonstrate the multimodal function of CAR-NKT cells in solid tumors, further supporting the rationale for developing CAR-NKT therapies in the clinic.
Journal • CAR T-Cell Therapy
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
HAVCR2 expression
3ms
Tim-3 Is Required for Regulatory T Cell-Mediated Promotion of T Cell Exhaustion and Viral Persistence during Chronic Lymphocytic Choriomeningitis Virus Infection. (PubMed, J Immunol)
Our findings demonstrate that modulation of a single surface protein on Tregs can lead to a reduction in viral burden, limit T cell exhaustion, and enhance gp33-specific T cell response. These studies may help to identify Tim-3-directed therapies for the management of persistent infections and cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
HAVCR2 expression
3ms
PD-1+ and TIM-3+ T cells widely express common γ-chain cytokine receptors in multiple myeloma patients, and IL-2, IL-7, IL-15 stimulation up-regulates PD-1 and TIM-3 on T cells. (PubMed, Oncol Res)
Differences in common γ-chain cytokine receptor expression between PD-1+ and TIM-3+ T cells may reflect functional dissimilarity of these cell subsets. Checkpoint blockade appears to alleviate lymphopenia-induced proliferation of PD-1+ T cells but may raise the possibility of immune-mediated adverse events.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL7R (Interleukin 7 Receptor) • IL15 (Interleukin 15) • IL7 (Interleukin 7)
|
CD8 expression • CD8 positive • HAVCR2 expression • IL2RA expression
3ms
Features and prognostic significance of soluble TIM-3 and its ligands Gal-9 and CEACAM1 levels in the diagnostic bone marrows of adult acute myeloid leukemia patients. (PubMed, J Leukoc Biol)
Furthermore, soluble TIM-3 level tended to have positive correlation with the percentage of non-blast myeloid TIM-3+ cells in nucleated cells in AML (r = 0.48, p = 0.073). Therefore, the high soluble TIM-3 level in the diagnostic BM plasma predicted poor outcome in adult AML patients, and high sGal-9 level was associated with relapse after allo-HSCT.
Journal • IO biomarker
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CEACAM1 (CEA Cell Adhesion Molecule 1)
|
HAVCR2 expression
3ms
In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pertuzumab. (PubMed, Int J Mol Sci)
HER2-targeted therapy plus chemotherapy demonstrated high efficacy in most patients, reducing the statistical power for finding immunological markers. However, NK subset phenotypes correlated better with response groups, and numerous changes in the percentage of leukocytes and T and NK cells, as well as changes in the functionality of NK cells, were observed in most patients after treatment, encouraging further research into these immune populations.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
EGFR positive • HAVCR2 expression
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
3ms
Phenotypic profiling of human induced regulatory T cells at early differentiation: insights into distinct immunosuppressive potential. (PubMed, Cell Mol Life Sci)
Using mass-spectrometry-based proteomics, we showed that sorted CD103+ iTregs express factors associated with immunosuppression. Overall, our study highlights that during early stages of differentiation, iTregs resemble memory-like Treg features with immunosuppressive activity, and provides opportunities for further investigation into the molecular mechanisms underlying Treg function.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CCR4 (C-C Motif Chemokine Receptor 4) • IL2RA (Interleukin 2 receptor, alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CCR7 (Chemokine (C-C motif) receptor 7) • FOXP3 (Forkhead Box P3) • ITGAE (Integrin Subunit Alpha E) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
|
LAG3 expression • HAVCR2 expression
3ms
Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy. (PubMed, Biomed Pharmacother)
These findings emphasize the impact of the optimal design of CAR constructs that provide efficient function. In the context of anti-TIM3 CAR T cells, using a CD8α spacer and transmembrane domain with TNFR-based costimulation is a promising CAR design to improve anti-TIM3 CAR T cell function for AML therapy.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD27 (CD27 Molecule)
|
HAVCR2 expression
8ms
The effects of HIV and oncogenic human papillomavirus on the tumor immune microenvironment of penile squamous cell carcinoma. (PubMed, PLoS One)
In conclusion, the tumor microenvironment of penile squamous cell carcinoma seems to be affected by both HIV and HPV infections. TIM3 appears to be a potential therapeutic target in PSCC patients with hrHPV infections.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • LAG3 expression • HAVCR2 expression
8ms
A Pathologically Friendly Strategy for Determining the Organ-specific Spatial Tumor Microenvironment Topology in Lung Adenocarcinoma Through the Integration of snRandom-seq and Imaging Mass Cytometry. (PubMed, Adv Sci (Weinh))
Immunosuppressive sites, including brain and liver metastases, are deposited with collagen I, and T cells at these sites highly express TIM-3. This study originally deciphers the single-cell landscape of the organ-specific TME at both cellular and spatial levels for LUAD, indicating the necessity for organ-specific treatment approaches.
Journal
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
|
HAVCR2 expression
8ms
The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status. (PubMed, Biomedicines)
Patients with the genetic characteristics of MSI-H cancer showed higher expression levels of ICMs than those in patients with MSS cancer, and predominantly, two or more ICMs were concurrently expressed. Our findings highlight the potential efficacy of the dual-blockade approach in immunotherapy, particularly in patients with MSI-H CRC.
Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
MSI-H/dMMR • HAVCR2 expression
8ms
Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy. (PubMed, Clin Cancer Res)
Several iTMEs exist during tumor evolution and NACT impact on iTME is heterogeneous. Clustering analysis of patients, unravels several IC subsets within OC and can guide future personalized approaches. Targeting different checkpoints such as TIM-3, LAG-3 and IDO-1, more prevalent than PD-L1, could more effectively harness anti-tumor immunity in this anti-PD-L1 resistant malignancy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • CD8 expression • HAVCR2 expression • IDO1 expression • FOXP3 expression
8ms
Relationship Between Tim-3 and Galectin-9 Expression Levels, Clinical Pathological Characteristics, and Prognosis in Patients After Radical Resection of Colorectal Cancer (PubMed, Sichuan Da Xue Xue Bao Yi Xue Ban)
They are identified as independent influencing factors that may trigger adverse prognostic events in patients. These findings suggest that Tim-3 and galectin-9 have potential as new therapeutic targets and clinical indicators.
Journal • IO biomarker
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • LGALS9 (Galectin 9)
|
HAVCR2 expression • HAVCR2 overexpression
8ms
Co-expression of immune checkpoints in glioblastoma revealed by single-nucleus RNA sequencing and spatial transcriptomics. (PubMed, Comput Struct Biotechnol J)
In addition, multimodal cross analysis integrated SnRNA-seq and ST, revealing complex intracellular communication and mapping the GBM tumor microenvironment. This study reveals novel molecular characteristics of GBM, co-expression of immune checkpoints, and potential therapeutic targets, contributing to improving the understanding and treatment of GBM.
Journal • IO biomarker
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • VSIR (V-Set Immunoregulatory Receptor)
|
HAVCR2 expression
8ms
Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis. (PubMed, Elife)
In ICI-ILD, we found an increase in CD57+ CD8+ T cells expressing immune checkpoints (TIGIT+ LAG3+ TIM-3+ PD-1+), FCRL5+ B cells, and CCR2+ CCR5+ CD14+ monocytes. These findings uncover the diverse immunophenotypes and possible pathomechanisms of cancer treatment-related pneumonitis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD14 (CD14 Molecule) • CCR2 (C-C Motif Chemokine Receptor 2) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
CD8 expression • LAG3 expression • HAVCR2 expression
8ms
JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment. (PubMed, In Vitro Cell Dev Biol Anim)
CXADR can inhibit the proliferation of cancer cells and promote the apoptosis. JAML agonist can effectively treat colorectal cancer by regulating CD8+ T cells.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CXADR (CXADR Ig-Like Cell Adhesion Molecule)
|
CD8 overexpression • CD8 expression • HAVCR2 expression • JAML overexpression
9ms
CircPVT1 promotes migration and invasion by regulating miR-490-5p/HAVCR2 axis in osteosarcoma cells. (PubMed, J Cell Mol Med)
Additionally, circPVT1 upregulated HAVCR2 expression via sequestering miR-490-5p, thereby orchestrating the migration and invasion in osteosarcoma cells. CircPVT1 orchestrates osteosarcoma migration and invasion by regulating the miR-490-5p/HAVCR2 axis, underscoring its potential as a promising therapeutic target for osteosarcoma.
Journal
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • MIR490 (MicroRNA 490) • PVT1 (Pvt1 Oncogene)
|
HAVCR2 expression • HAVCR2 overexpression • miR-490 expression
9ms
Tissue Inhibitor of Metalloproteinase 3: Unravelling Its Biological Function and Significance in Oncology. (PubMed, Int J Mol Sci)
However, the relationship between TIMP3 and endometrial cancers remains unclear. TIMP3 may be a useful biomarker for gynaecological cancers and is a potential target for future cancer therapy.
Review • Journal
|
TIMP3 (TIMP Metallopeptidase Inhibitor 3)
|
HAVCR2 expression
9ms
TIM3 and CTLA4 immune checkpoint polymorphisms are associated with acute myeloid leukemia in Saudi Arabia. (PubMed, Hematology)
A significantly higher expression of TIM-3 in the blood of individuals with AML was observed. This is the first study focusing on single nucleotide polymorphisms (SNPs) for CTLA-4 and TIM-3 in acute myeloid leukemia patients in a Saudi community and could be a potential new prognostic factor for this disease.
Journal • IO biomarker
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
HAVCR2 expression
9ms
Viewing the immune checkpoint VISTA: landscape and outcomes across cancers. (PubMed, ESMO Open)
High VISTA expression correlates with high BTLA, TIM-3, and TNFRSF14 checkpoint-related molecules and with poorer post-immunotherapy survival in pancreatic cancer, consistent with prior literature indicating that VISTA is prominently expressed on CD68+ macrophages in pancreatic cancers and requiring validation in larger prospective studies. Immunomic analysis may be important for individualized precision immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TNFRSF14 (TNF Receptor Superfamily Member 14) • CD68 (CD68 Molecule) • BTLA (B And T Lymphocyte Associated) • VSIR (V-Set Immunoregulatory Receptor)
|
HAVCR2 expression • BTLA elevation
9ms
Germline HAVCR2/TIM-3 Checkpoint Inhibitor Receptor Deficiency in Recurrent Autoinflammatory Myocarditis. (PubMed, J Clin Immunol)
We conclude that TIM-3 deficiency due to homozygous HAVCR2 c.245 A > G p.Tyr82Cys pathogenic variant in the patient described here is associated with autoinflammatory symptoms limited to early onset recurrent febrile myocarditis. Excessive IL-1β production and defective regulation of T cell proliferation may contribute to this clinical condition responsive to anakinra treatment.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1) • CD14 (CD14 Molecule) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta)
|
HAVCR2 expression
|
Kineret (anakinra)
9ms
Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma. (PubMed, Leuk Lymphoma)
It can also improve the abnormal DLBCL microenvironment in which immune escape occurs, and inhibit immune escape. This study provides a new therapeutic idea for the exploration of individualized precision therapy for patients with malignant lymphoma.
Journal • PD(L)-1 Biomarker • IO biomarker
|
NOTCH1 (Notch 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
|
PD-1 expression • HAVCR2 expression • NOTCH1 expression
|
Epidaza (chidamide)
9ms
CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude. (PubMed, J Transl Med)
In summary, GCs impacted phenotype and function of untransduced and CAR T cell with different magnitude. The nature of the CAR costimulatory domain influenced the magnitude of CAR T cell response to GCs.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • MSLN (Mesothelin) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
PD-1 expression • LAG3 expression • HAVCR2 expression
|
dexamethasone
9ms
Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms. (PubMed, Cancer Invest)
A low-to-intermediate positive correlation was observed between PD-L1 and TIM-3 expressions (rho: 0.333, p < 0.01). Although PD-L1 expression was higher in grade 3 NET/NEC, MSI status was prominent in grade 1/2 NET.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TNFSF4 (TNF Superfamily Member 4)
|
PD-L1 expression • PD-L1 overexpression • LAG3 expression • HAVCR2 expression
9ms
Preclinical • Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • MSLN (Mesothelin) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • GZMB (Granzyme B)
|
LAG3 expression • HAVCR2 expression
10ms
Sirtuin 2 up-regulation suppresses the anti-tumour activity of exhausted natural killer cells in mesenteric lymph nodes in murine colorectal carcinoma. (PubMed, Scand J Immunol)
Moreover, Sirt2 silencing partially ameliorates the defects in glycolysis and mitochondrial respiration of exhausted NK cells, as evidenced by increases in glycolytic capacity, glycolytic reserve, basal respiration, maximal respiration and spare respiration capacity. Accordingly, Sirt2 negatively regulates the tumoricidal activity of exhausted NK cells in CRC.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • KLRC1 (Killer Cell Lectin Like Receptor C1)
|
HAVCR2 expression • IFNG expression